Healthcare / Medical Instruments & SuppliesASX
$0.26
-0.05 (-14.75%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 22%
FCF escenarios
weak_data · normalized FCF $7.4M · quality 50.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
56/100
C
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$97M
P/E
13.0x
↓EV/EBITDA
7.8x
↓ROE
11.5%
↑Gross Margin
52.0%
↑Debt/Equity
0.08
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+31.4%
FCF CAGR
+202.0%
FCF margin
10.7%
FCF / Net income
1.46x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $81.4M · net income $5.9M · FCF $8.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $81.4M | $81.4M | $58.2M | $42.0M | $35.9M |
| Net Income | $5.9M | $5.9M | $7.1M | $2.3M | $2.3M |
| EBITDA | $10.9M | $10.9M | $8.0M | $3.6M | $3.5M |
| EPS | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 |
| Gross Margin | 52.0% | 52.0% | 52.7% | 53.4% | 52.5% |
| Operating Margin | 12.3% | 12.3% | 10.0% | 4.3% | 6.0% |
| Net Margin | 7.3% | 7.3% | 12.2% | 5.4% | 6.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.08 | 0.08 | 0.04 | 0.02 | 0.04 |
| Current Ratio | 2.15 | 2.15 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $8.7M | $8.7M | $7.4M | $-1.3M | $315000.00 |
| Returns | |||||
| ROE | 11.5% | 11.5% | 15.9% | 9.0% | 10.1% |
| Valuation | |||||
| P/E | 13.00 | 13.00 | 8.30 | 21.84 | 14.06 |
| EV/EBITDA | 7.84 | 7.84 | 5.86 | 12.70 | 7.44 |
| P/B | 1.86 | 1.86 | 1.32 | 1.97 | 1.42 |
| Growth & Yield | |||||
| Revenue Growth | 40.0% | 40.0% | 38.5% | 17.0% | — |
| EPS Growth | -30.1% | -30.1% | 194.2% | -4.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
13.0%
EPS terminal req.
$0.02
Spread vs growth
-43.1%
5Y implied EPS CAGR
11.8%
EPS terminal req.
$0.03
Spread vs growth
-41.9%
10Y implied EPS CAGR
10.9%
EPS terminal req.
$0.04
Spread vs growth
-41.0%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-14.8%
Start / end P/E
13.3x → 16.2x
EPS bridge
0.02 → 0.02
Residual
-6.6%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.